In both these instances, conditions tend to improve due to body weight dropping making it important to recognise which benefits are due to weight loss rather than any specific pharmacological action
Since 2005, there have been several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), including lixisenatide, exenatide, albiglutide, dulaglutide and liraglutide, recommended for the treatment of T2D approved by the US Food and Drug Administration (FDA)
They can also assess whether adherence challenges stem from side effects, injection technique difficulties, or other barriers that might be addressed through education or support
References FDA Bremelanotide (Vyleesi) prescribing information: dosing, safety, and use limitations NCBI Bookshelf (LiverTox) Bremelanotide: mechanism, clinical use, and hepatic safety profile PMC Bremelanotide for treatment of female hypoactive sexual desire disorder: clinical trial review Mayo Clinic Bremelanotide (subcutaneous route): side effects, dosage, and precautions PubMed Evaluation of Melanotan-II: pilot phase-I clinical study on safety and efficacy RxList Melanotan-II: uses, side effects, dosing, and precautions overview Bachem Handling and storage guidelines for peptides: lyophilized and reconstituted stability NCBI Bookshelf (WHO) Best practices for injections and related procedures: asepsis and technique Healthline Subcutaneous injection: technique, sites, and step-by-step guidance CDC Vaccine administration: subcutaneous injection angle and site selection Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
The choice between them depends on personal preference, lifestyle, and individual tolerability
"Period insomnia" is the name for sleep issues related to the menstrual cycle
